<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1167</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2019-18-3-23-30</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Identification of immunogenic mutant neoantigens in the genome of murine melanoma</article-title><trans-title-group xml:lang="ru"><trans-title>Выявление иммуногенных мутантных неоантигенов в геноме меланомы мышей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8462-2178</contrib-id><name-alternatives><name xml:lang="en"><surname>Kosorukov</surname><given-names>V. S.</given-names></name><name xml:lang="ru"><surname>Косоруков</surname><given-names>В. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashyrskoe Shosse, Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6688-8423</contrib-id><name-alternatives><name xml:lang="en"><surname>Baryshnikova</surname><given-names>M. A.</given-names></name><name xml:lang="ru"><surname>Барышникова</surname><given-names>М. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashyrskoe Shosse, Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24.</p></bio><email>ma_ba@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4660-8519</contrib-id><name-alternatives><name xml:lang="en"><surname>Kosobokova</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Кособокова</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashyrskoe Shosse, Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1557-7593</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakovishina</surname><given-names>D. Yu.</given-names></name><name xml:lang="ru"><surname>Яковишина</surname><given-names>Д. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>30A Leninskiy Prospekt, Moscow 119049.</p></bio><bio xml:lang="ru"><p>119049 Москва, Ленинский проспект, 30А.</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1014-7677</contrib-id><name-alternatives><name xml:lang="en"><surname>Ershova</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Ершова</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>30A Leninskiy Prospekt, Moscow 119049.</p></bio><bio xml:lang="ru"><p>119049 Москва, Ленинский проспект, 30А.</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9285-0309</contrib-id><name-alternatives><name xml:lang="en"><surname>Pekov</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Пеков</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>30A Leninskiy Prospekt, Moscow 119049.</p></bio><bio xml:lang="ru"><p>119049 Москва, Ленинский проспект, 30А.</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ksivalue LLC</institution></aff><aff><institution xml:lang="ru">ООО «Ксивелью»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-10-16" publication-format="electronic"><day>16</day><month>10</month><year>2019</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>23</fpage><lpage>30</lpage><history><date date-type="received" iso-8601-date="2019-10-15"><day>15</day><month>10</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-10-15"><day>15</day><month>10</month><year>2019</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1167">https://bioterapevt.abvpress.ru/jour/article/view/1167</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>. One of the promising approaches to cancer immunotherapy is the generation of personal antitumor vaccines that provides immune system recognition of mutant tumor neoantigenes.</p><p><bold>The aim</bold> of this study was to develop bioinformatic approaches for melanoma NGS-sequencing data analysis. On the basis of data obtained, to predict the peptides capable of inducing an immune response against B16F10 mouse melanoma.</p><p><bold>Materials and methods</bold>. Exom and transcriptom of B16/F10 melanoma tumor tissue and normal tissue of C57BL/6 mice were sequenced. Library sequencing procedure was performed on Illumina HiSeq 2500platform, quality analysis of all obtained libraries was performed using FastQC and MultiQC. The obtainedfiles were usedfor further bioinformatics analysis. The GATKMuTect2 and Strelka were used for searching the mutations in tumor samples.</p><p><bold>Results</bold>. Identification of somatic mutations specific for tumor was based on the analysis of few mice tumors. Here we show that mutations in different tumor samples significantly overlap, but are not identical. Prediction of short peptides affinity to the mouse main histocompatibility complex (MHC) H2 was performed using netMHCpan version 3.0. Mutations such as missense and frameshift were used to predict short peptides that could trigger an immune response. Transcriptome data confirm that mutated alleles are expressed in tumors. Vaxrank pipeline predicted immunogenic peptides with a length of25—27. We also present the synthesis and solubility of these peptides. </p><p><bold>Conclusion</bold>. A bioinformatic approach has been developed to predict peptides capable of increasing immune response of mouse melanoma B16/F10.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. Одним из перспективных подходов к иммунотерапии рака является создание персонализированных противоопухолевых вакцин, направленных на усиление распознавания иммунной системой мутантных опухолевых неоантигенов.</p><p><bold>Цель исследования</bold> — разработка биоинформатического подхода для анализа данных NGS-секвенирования образцов меланомы и нормальной ткани и предсказания пептидов, способных вызывать иммунный ответ на модели мышиной меланомы B16F10. Материалы и методы. Секвенировали экзом и транскриптом опухолевой ткани меланомы B16F10 и нормальной ткани мышей линии С57Bl/6. Процедура секвенирования библиотек была произведена на платформе IlluminaHiSeq 2500, анализ качества всех полученных библиотек был выполнен с помощью программ FastQC и MultiQC. Полученные файлы были использованы для дальнейшего биоинформатического анализа. Для поиска мутаций в образцах опухоли использовали программы GATKMuTect2 и Strelka. </p><p><bold>Результаты</bold>. В образцах материала, полученного от нескольких мышей, проведен поиск соматических мутаций, присутствующих только в опухолях и отсутствующих в нормальной ткани, показано, что мутации в разных образцах опухоли значительно перекрываются, но не идентичны. Предсказание коротких пептидов, аффинных к главному комплексу гистосовместимости (МНС) мыши H-2, было проведено с использованием модели netMHCpan (версия 3.0), использующей глубокие искусственные нейронные сети. Для предсказания коротких пептидов, способных вызвать иммунный ответ, использовались мутации типа миссенс и фреймшифт. Для подтверждения, что мутированные аллели экспрессируются в опухоли, использовали транскриптомные данные. С помощью пайплайна Vaxrank были предсказаны иммуногенные пептиды длиной 25—27аа, представлены параметры их синтезируемости и растворимости.</p><p><bold>Выводы</bold>. Разработан биоинформатический подход для предсказания пептидов, способных вызывать иммунный ответ на мо¬дели мышиной меланомы B16F10.</p></trans-abstract><kwd-group xml:lang="en"><kwd>bioinformatic analysis</kwd><kwd>neoantigen</kwd><kwd>antitumor vaccine</kwd><kwd>melanoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>биоинформатический анализ</kwd><kwd>неоантиген</kwd><kwd>противоопухолевая вакцина</kwd><kwd>меланома</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was carried out with the financial support of the Ministry of Health of Russia in the framework of the experimental scientific development No АААА-А18-118032290146-5.</funding-statement><funding-statement xml:lang="ru">Работа была выполнена при финансовой поддержке Минздрава России в рамках экспериментальной научной разра-ботки № АААА-А18-118032290146-5.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Baryshnikova M.A., Kosobokova E.N., Kosorukov V.S. Neoantigens in tumor immunotherapy. Rossiysky bioterapevtichesky zhurnal = Russian Journal of Biotherapy 2018;17(2):5—14. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Барышникова М.А., Кособокова Е.Н., Косоруков В.С. Неоантигены в иммунотерапии опухолей. Российский биотерапевтический журнал 2018;17(2):6—14. DOI: 10.17650/1726-9784-2018-7-2-6-14.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Robbins P.F., El-Gamil M., Li Y.F. et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92. DOI: 10.1084/jem.183.3.1185.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Castle J.C., Kreiter S., Diekmann J. et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012;75(5):1081-90. DOI: 10.1158/0008-5472.CAN-11-3722.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Robbins P.F., Lu Y.C., El-Gamil M. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19(6) /747-52. DOI: 10.1038/nm.3161.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ott P.A., Hu Z., Keskin D.B. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. DOI: 10.1038/nature22991.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Singh H., Raghava G.P. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003;19(8): 1009-14. DOI: 10.1093/bioinformatics/btg108.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Reche P.A., Glutting J.P. Enhancement to the RANKPEP resource for the pre-diction of peptide binding to MHC mol-ecules using profiles. Immunogenetics 2004;56(6):405-19. DOI: 10.1007/s00251-004-0709-7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>McGranahan N., Furness A.J., Rosen-thal R. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to im-mune checkpoint blockade. Science 2016;351(6280):1463-9. DOI: 10.1126/science.aaf1490..</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Jurtz V., Paul S., Andreatta M. еt al. NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol 2017;199(9): 3360-8. DOI: 10.4049/jimmunol.1700893.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lundegaard C., Lamberth K., Harndahl M. et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008;36(Web Server issue):509-12. DOI: 10.1093/nar/gkn202.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rubinsteyn A., Hodes I., Kodysh J., Hammerbacher J. Vaxrank: A computational tool for designing per-sonalized cancer vaccines. available at: https://www.biorxiv.org/content/early/2018/10/18/142919</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rubinsteyn A., Kodysh J., Hodes I. et al. Computational pipeline for the PGV-001 neoantigen vaccine trial. Front Immunol 2018;8: 1807. DOI: 10.3389/fimmu.2017.01807.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157(1):105-32. DOI: 10.1016/0022-2836(82)90515-0.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hebditch M., Carballo-Amador M.A., Charonis S. et al. Protein-Sol: a web tool for predicting protein solubility from sequence. Bioinformatics 2017;33(19):3098-100. DOI: 10.1093/bioinformatics/btx345.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Saunders C.T., Wong W.S., Swamy S. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinfor-matics 2012;28(14):1811-7. DOI: 10.1093/bioinformatics/bts271.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Cibulskis K., Lawrence M.S., Carter S.L. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31(3):213-9. DOI: 10.1038/nbt.2514.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lower M., Renard B.Y., de Graaf J. et al. Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol 2012;8(9):1002714. DOI: 10.1371/journal.pcbi.1002714.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Castle J.C., Lower M., Boegel S. et al. Mutated tumor alleles are expressed according to their DNA frequency. Sci Rep 2014;4:4743. DOI: 10.1038/srep04743.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kreiter S., "Vbrmehr M., van de Roemer N. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015;520(7549):692-6. DOI: 10.1038/nature14426.</mixed-citation></ref></ref-list></back></article>
